Full Press Release Details
Announces a 1:20 Reverse Stock Split Effective Pre-Market Opening on July 28, 2023
Florida- July 27, 2023 - INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a
commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell medical device
and the intravaginal culture ("IVC") procedure it enables, announced today that it will effect a 1-for-20 reverse split of
its issued and outstanding and authorized common stock effective as of 12:01 a.m. Eastern Time on July 28, 2023. Commencing with the
opening of trading on The Nasdaq Capital Market on July 28, 2023, the Company's common stock will trade on a post-split basis under
the same trading symbol, "INVO".
a result of the reverse stock split, the CUSIP number for the Company's common stock will be 44984F401. As a result of the reverse
stock split, every 20 shares of issued and outstanding common stock will be exchanged for 1 share of common stock, with any fractional
shares being rounded up to the next higher whole share. Immediately after the reverse stock split becomes effective, the company will
have approximately 842,017 shares of common stock issued and outstanding. In addition, a proportionate adjustment will be made to the
company's authorized shares of common stock such that the Company shall have 6,250,000 shares of authorized common stock after
the effective time of the reverse stock split.
reverse stock split is primarily intended to bring the Company into compliance with Nasdaq's $1.00 per share minimum bid price
requirement for continued listing. However, no assurance can be given that such reverse stock split will enable the Company to regain
compliance with the Nasdaq minimum bid price requirement.
are a commercial-stage fertility company dedicated to expanding the assisted reproductive technology ("ART") marketplace
by making fertility care accessible and inclusive to people around the world. Our primary mission is to implement new medical technologies
aimed at increasing the availability of affordable, high-quality, patient-centered fertility care. Our flagship product is INVOcell ,
a revolutionary medical device that allows fertilization and early embryo development to take place in vivo within the woman's
body. This treatment solution is the world's first intravaginal culture technique for the incubation of oocytes and sperm during
fertilization and early embryo development. This technique, designated as "IVC", provides patients a more natural, intimate,
and more affordable experience in comparison to other ART treatments. We believe the IVC procedure can deliver comparable results at
a fraction of the cost of traditional in vitro fertilization ("IVF") and is a significantly more effective treatment than
intrauterine insemination ("IUI"). Our commercialization strategy is focused on the opening of dedicated "INVO Centers"
offering the INVOcell and IVC procedure (with three centers in North America now operational), in addition to continuing to distribute
and sell our technology solution into existing fertility clinics. For more information, please visit www.invobio.com.
release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform
Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business
strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations,
as well as statements that include words such as "anticipate," "if," "believe," "plan,"
"estimate," "expect," "intend," "may," "could," "should," "will,"
and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties, and contingencies,
many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated
results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements
include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation
to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
more information, please contact: